Effective Management of Acute and Chronic Pain with Opioid Analgesics, 2nd Edition _ ________________
(iii) chronic debilitating neurological conditions characterized as a movement disorder or exhibiting seizure, convulsive or spasm activity, designated as code C; (iv) relief of pain in patients suffering from conditions or diseases known to be chronic or incurable, designated as code D; (v) narcolepsy, designated as code E; or (vi) hormone deficiency states in males, gynecologic conditions that are responsive to treatment with anabolic steroids or chorionic gonadotropin, metastatic breast cancer in women, anemia and angioedema, designated as code F. (2) Such prescription shall specify the condition being treated on the face of the prescription. The practitioner issuing such prescription shall either: (i) specify the name of such condition on the face of the prescription; or (ii) specify a code on the prescription to denote the condition for which the prescription has been issued, in accordance with codes designated in paragraph (d)(1) of this section. (3) Either the name of the condition or one of the designated codes shall fulfill the requirement in: (i) section 3332(3) of the Public Health Law for the specific condition to be given on the face of the prescription; and (ii) section 3333(1) of the Public Health Law for the statement that the controlled substance has been prescribed to treat one of the conditions that have been enumerated by the regulations of the commissioner as warranting the prescribing of greater than a 30 days’ supply of a controlled substance. (e) Such official New York State prescription or out-of-state written prescription for a patient enrolled in a hospice program or for a patient residing in a Residential Health Care Facility (RHCF) may be transmitted by the practitioner, or a person authorized by the practitioner, to the dispensing pharmacy by facsimile, provided; (1) The hospice program or RHCF is licensed or approved by the Department; (2) The dispensing pharmacy has a written agreement or contract with the hospice program or “RHCF” to dispense controlled substances to a patient of such program or facility; (3) The practitioner shall note on the prescription that the patient is a “hospice patient” or “RHCF patient”; and (4) Within 72 hours, the prescribing practitioner shall cause to be delivered to the pharmacist the original official New York State prescription or the original out-of-state written prescription. If the pharmacist fails to receive such prescription, he/she shall notify the Department in writing or electronically within 7 days from the date of dispensing the substance. (f) An official New York State prescription or an out-of-state written prescription for a Schedule II narcotic substance or for those controlled substances listed in paragraph (a) of this Section to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, subcutaneous or intraspinal infusion may be transmitted by the practitioner, or a person authorized by the practitioner, to the dispensing pharmacy by facsimile. Within 72 hours, the prescribing practitioner shall cause to be delivered to the pharmacist the original official New York State prescription or the original out-of-state written prescription. If the pharmacist fails to receive such prescription, he/she shall notify the Department in writing or electronically within 7 days from the date of dispensing the substance. (g) When an official New York State prescription or an out-of-state written prescription prepared by a practitioner is incomplete, the practitioner may orally furnish the missing information to the pharmacist and authorize him or her to enter such information on the prescription. The pharmacist shall write the date he or she received the oral authorization on the prescription and shall affix his or her signature. This procedure shall not apply to unsigned or undated prescriptions or where the name and/or quantity of the controlled substance is not specified or where the name of the ultimate user is missing. The pharmacist is not required to obtain authorization from the practitioner to enter the patient’s address, sex or age if the pharmacist obtains this information through a good-faith effort. (h) A practitioner may orally authorize a pharmacist to change information on an official New York State prescription or an out-of- state written prescription. This procedure shall not apply to the practitioner’s signature, date the prescription was signed by the practitioner, drug name or name of the ultimate user. The pharmacist shall write the date he or she received the oral authorization on the prescription, the reason for the change and his or her signature. The pharmacist shall also indicate the change on the prescription and initial the change. (i) When a pharmacist fills a prescription under subdivision (g) or subdivision (h) of this section, in a manner that would require the pharmacist to make a notation on the prescription if the prescription were written, the pharmacist shall make the same notation electronically when filling an electronic prescription and retain the annotation electronically in the prescription record. (j) When a practitioner is notified that an electronic prescription was not successfully delivered, the practitioner shall indicate on any written or oral prescription issued as a replacement of the original electronic prescription that the prescription was originally transmitted electronically, to which pharmacy the prescription was originally transmitted, and that the original transmission failed. (k) If the content of any of the information required by this Part for a prescription is altered during the transmission of an electronic prescription, the prescription is deemed to be invalid and the pharmacy may not dispense the controlled substance.
34
MDNY1026
Powered by FlippingBook